William Blair initiated coverage on Natera Inc. (NASDAQ:NTRA), highlighting the company's strong positioning in the emerging minimal residual disease (MRD) testing market and its broader growth outlook driven by multiple business segments.

MRD refers to the small number of cancer cells remaining in a patient's body after treatment, even when in remission and with no symptoms.

MRD testing is highly sensitive and is crucial for monitoring blood cancers (leukemia, lymphoma, myeloma) to predict relapse, guide treatment adjustments, and determine prognosis.

Market Opportunity And Growth Outlook

Analyst Andrew Brackmann said the MRD testing market, estimated at more than $20 billion, is still in early stages, with penetration currently in the mid- to high-single digits.

While multiple players are expected to gain traction, he emphasized that Natera is particularly well-positioned to benefit from increasing adoption in solid tumors.

Brackmann estimates Natera generated close to $1 billion in ...